CORDIS
EU research results

CORDIS

English EN

Valorisation of splice-switching oligonucleotides for lung cancer therapy

Project information

Grant agreement ID: 790429

Status

Closed project

  • Start date

    1 April 2018

  • End date

    30 September 2019

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 149 894

  • EU contribution

    € 149 894

Hosted by:

FUNDACIO CENTRE DE REGULACIO GENOMICA

Spain

Objective

Here we propose to test the therapeutic potential of a novel class of reagents, known as splicing-modifying antisense oligonucleotides, in preclinical models of lung adenocarcinoma, including patient-derived tumours in mice. Alternative splicing is a major mechanism of gene regulation by which different messenger RNAs and proteins are generated from a single gene, often displaying distinct, even antagonistic functions. Alterations in alternative splicing have been linked with a plethora of pathologies ranging from neurodegenerative disease to cancer. As a result of detailed mechanistic analyses of alternative splicing regulation in the context of the ERC-funded MASCP project, we have identified antisense oligonucleotides that modulate alternative splicing of a gene that plays key roles in the control of lung cancer cell proliferation. These reagents repress cell growth in vitro as well as inhibit tumour growth when administered intranasally in mouse models of lung adenocarcinoma. The main experimental goal of the ERC PoC proposal is to test the therapeutic value of the antisense oligonucleotides in a variety of patient-derived xenografts in mice, alone or in combination with other treatments, including chemotherapy. This will require previous optimization of dose and delivery route, which is being carried out with available support from other healthcare innovation funds. These goals are aligned with requests from various stakeholders, and funding from the ERC PoC program will be critical for successful valorisation of our assets, intellectual property protection and recruitment of venture capital to establish a spin-off company. Given the high incidence, poor prognosis and lack of efficient therapies for lung cancer, the work proposed can translate fundamental knowledge on molecular mechanisms of gene regulation derived from the ERC-funded MASCP project into applications whose valorisation can bridge the gap to market and provide added value for society.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Host institution

FUNDACIO CENTRE DE REGULACIO GENOMICA

Address

Carrer Doctor Aiguader 88
08003 Barcelona

Spain

Activity type

Research Organisations

EU Contribution

€ 149 894

Beneficiaries (1)

FUNDACIO CENTRE DE REGULACIO GENOMICA

Spain

EU Contribution

€ 149 894

Project information

Grant agreement ID: 790429

Status

Closed project

  • Start date

    1 April 2018

  • End date

    30 September 2019

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 149 894

  • EU contribution

    € 149 894

Hosted by:

FUNDACIO CENTRE DE REGULACIO GENOMICA

Spain